Her2 Brands

Groundbreaking HER2-targeted biologic cancer therapy (trastuzumab) developed by Genentech and owned by Roche, FDA approved September 25, 1998, that transformed the treatment of HER2-positive breast cancer and now faces biosimilar competition from multiple approved alternatives.

Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1) developed by Genentech using ImmunoGen's DM1 cytotoxic technology, FDA approved February 22, 2013, for HER2-positive metastatic breast cancer and later for early-stage HER2-positive breast cancer following the KATHERINE trial.

Roche's HER2-targeted biologic (pertuzumab) developed by Genentech, FDA approved June 8, 2012, that targets a different HER2 domain than Herceptin and is used in combination with Herceptin and chemotherapy for HER2-positive breast cancer in both metastatic and early-stage settings.